Cartesian Therapeutics Inc. Cash Flow Quality Index
Cartesian Therapeutics Inc. cash flow quality index. Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Quality Index of -1.10x as of June 2025. Operating cash flow of $-17.52 Million is below net income of $15.89 Million, suggesting accrual-heavy earnings not yet converted to cash. See Cartesian Therapeutics Inc. (RNAC) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Cartesian Therapeutics Inc. (2022–2022)
Cash flow quality index of Cartesian Therapeutics Inc. from 2022 to 2022. Historical Cash Flow Quality Index for Cartesian Therapeutics Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore RNAC operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cartesian Therapeutics Inc. Cash Flow Quality Index by Year (2022–2022)
Cartesian Therapeutics Inc. cash flow quality index by year from 2022 to 2022. Year-by-year earnings quality comparison for Cartesian Therapeutics Inc.. For the full cash flow conversion analysis, see cash flow conversion of Cartesian Therapeutics Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | -0.89x | $-31.63 Million | $35.38 Million | — |